Fortress Biotech reports record FY2022 revenue $75.7M, net loss $(86.6)M; BLA accepted for cosibelimab

Fortress Biotech, Inc.

Record consolidated net revenue of $75.7M for FY2022, up from $68.8M in FY2021; $71.0M from dermatology products.
GAAP net loss attributable to common stockholders of $(86.6)M ($(0.97)/share) vs $(64.7)M ($(0.79)/share) in FY2021.
Cash, equivalents and restricted cash $181.0M at Dec 31, 2022, down from $308.0M at Dec 31, 2021.
FDA accepted BLA for cosibelimab (anti-PD-L1) for cSCC; PDUFA goal date Jan 3, 2024; no advisory committee planned.
Expects to complete rolling NDA for CUTX-101 (Menkes disease) and submit NDA for DFD-29 (rosacea) in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Fortress Biotech, Inc. reported full-year ended December 31, 2022 results: revenue $75.7 million.

Period: full-year ended December 31, 2022
Revenue: $75.7 million
Result: reported results

Exact text from the filing

We also generated record consolidated net revenues of $75.7 million

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Fortress Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-005150

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.